Swedish-British drug firm AstraZeneca said on Monday that late stage trials of its coronavirus disease 2019 (Covid-19) vaccine developed with Oxford University were “highly effective” in preventing the disease.
The results are based on interim analysis of trials in the United Kingdom and Brazil of the vaccine developed by Oxford University and manufactured by AstraZeneca. No hospitalizations or severe cases of Covid-19 were reported from those receiving the vaccine, AstraZeneca said.
The drug firm has made a “no-profit” pledge to make its Covid-19 vaccine more widely available.
“These findings show that we have an effective vaccine that will save many lives. Excitingly that one of our dosing regimens may be around 90-percent effective,” said Professor Andrew Pollard, the chief investigator for the trial.
The trial looked at two different dosing regimens — a half dose of the vaccine followed by a full dose at least one month apart was 90-percent effective. A second regimen using two full doses one month apart was 62-percent effective. The combined results showed an average efficacy rate of 70-percent.Two other drugmakers, Pfizer and Moderna, last week reported preliminary results from late-stage trials showing their Covid-19 vaccines were almost 95-percent effective. SOVEREIGNPH